DANAHER CORP /DE/DHR
DANAHER CORP /DE/ Financial Overview 2020–2024
Danaher’s growth profile shifted violently from a 32.0% sales surge in FY2021 to a 10.5% contraction in FY2023, marking the definitive end of pandemic-driven demand. This volatility forced a strategic reset, as the company spun off non-core assets to focus exclusively on life sciences and diagnostics. The financial impact of this transition is evident in the earnings trajectory: diluted EPS climbed from $4.89 in FY2020 to a peak of $9.66 in FY2022, before normalizing to $5.29 at the close of FY2024.
Despite the bottom-line compression, recent operational metrics indicate a successful turnaround is underway. While FY2024 saw a 1.5% decline in core sales and significant restructuring costs—including a $432 million impairment charge recorded in Q2 2025—momentum has shifted. By Q3 2025, core sales rebounded to 3.0% growth, powered by a 9.0% revenue jump in the Biotechnology segment. Management has aggressively supported this transition with capital returns, executing $6.0 billion in share repurchases during FY2024 while maintaining $2.6 billion in cash as of late 2025 to fund ongoing strategic pivots.
Recent Developments (Q2 and Q3 2025)
Danaher accelerated its operational recovery through the middle of 2025, improving from 1.5% core sales growth in Q2 2025 to 3.0% in Q3 2025. While the Life Sciences segment faced headwinds—posting core declines of 2.5% and 1.0% in the second and third quarters, respectively—the Biotechnology unit became a clear engine of growth, delivering 6.5% core expansion in Q3 2025. Profitability also stabilized, with operating margins improving in the third quarter as the company moved past earlier impairment impacts. Management signaled strong conviction in this trajectory on September 9, 2025, by authorizing a new program to repurchase up to 35 million shares, adding to the $3.09 billion deployed in the first nine months.
Bullish investors view the 9.0% total revenue jump in Biotechnology and aggressive capital returns as evidence of a sustained pivot. Conversely, skeptics argue that continued weakness in genomics consumables leaves little room for error given the stock traded at a lofty 41.7x earnings as of the Q3 2025 report.
What to watch: stabilization in Life Sciences consumables demand; impacts of new trade tariffs on global supply chains.
Rev
$23.88B
FY2024
NI
$3.90B
FY2024
EPS
$5.33
FY2024
OCF
$6.69B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
DANAHER CORP /DE/ 8-K Report, Corporate Update (Feb 17, 2026)
Danaher Corporation (DHR) announced its entry into a definitive Agreement and Plan of Merger to acquire Masimo Corporation (MASI) for $180.00 per share in cash. This acquisition, structured as a merger where Masimo will become a wholly owned subsidiary of Danaher, represents a significant strategic move for Danaher. The transaction is subject to customary closing conditions, including antitrust approvals under the Hart-Scott-Rodino Act and certain non-U.S. regulatory clearances. Investors should note that this filing serves as an initial announcement of the merger agreement. Further details regarding the transaction, including the proxy statement to be filed by Masimo, will be crucial for a complete understanding of the deal's implications. Both companies have provided extensive disclosures regarding potential participants in the solicitation process and cautionary statements concerning forward-looking information, highlighting the inherent risks and uncertainties associated with the transaction's completion and its anticipated benefits.
DANAHER CORP /DE/ 8-K Report, Executive Changes (Feb 10, 2026)
Danaher Corporation (DHR) announced a change to its Board of Directors with the retirement of Jessica L. Mega, effective February 5, 2026. Dr. Mega's departure is attributed to increasing commitments from her other professional endeavors and is not a reflection of any disagreements with the company's operations, policies, or practices. This event, while noted, does not appear to signal any material operational or strategic shifts for Danaher at this time, but investors should monitor board composition for any long-term implications. The filing also includes the standard XBRL interactive data file. Investors should consider this an administrative update concerning board membership rather than a primary driver of near-term stock performance. The company continues its focus on its core business segments, and the absence of Dr. Mega from the board is not expected to impact the company's strategic direction or financial performance.
DANAHER CORP /DE/ 8-K Report, Financial Results (Jan 28, 2026)
Danaher Corporation (DHR) has filed an 8-K report on January 28, 2026, announcing its financial results for the year ended December 31, 2025. The report primarily serves to furnish a press release detailing these results, which is incorporated by reference as Exhibit 99.1. Investors should note that this information, while informative, is furnished and not deemed "filed" under Section 18 of the Securities Exchange Act of 1934, unless specifically incorporated into a future filing. The key takeaway for investors is that this filing provides the official announcement of Danaher's performance for the full fiscal year 2025, including fourth-quarter results. While the 8-K itself does not contain the financial data, it directs readers to the accompanying press release for the comprehensive details on revenue, profitability, and other key financial metrics. Investors are encouraged to review Exhibit 99.1 for a thorough understanding of the company's operational and financial condition.
DANAHER CORP /DE/ 8-K Report, Financial Results (Jan 12, 2026)
Danaher Corporation (DHR) has filed a Current Report (8-K) on January 12, 2026, providing an early look at its estimated financial performance for the fourth quarter of 2025. This release is in anticipation of the company's participation in the J.P. Morgan Healthcare Conference scheduled for January 13, 2026. While specific financial figures are not detailed within the 8-K itself, the filing incorporates by reference a press release and presentation slides that contain this estimated performance data. Investors should note that this information is furnished and not deemed "filed" under Section 18 of the Exchange Act, meaning it carries a different legal implication than a standard filing. The attached exhibits, including the press release and presentation slides, are the primary sources for understanding Danaher's preliminary Q4 2025 and full-year 2025 financial outlook. These documents are crucial for investors to assess the company's recent operational results and financial condition ahead of the J.P. Morgan conference.
DANAHER CORP /DE/ 8-K Report, Executive Changes (Nov 6, 2025)
Danaher Corporation (DHR) has filed a Current Report (8-K) primarily detailing a change in its Board of Directors. John T. Schwieters has informed the Board of his decision not to seek reelection at the upcoming 2026 annual meeting of shareholders, leading to his retirement from the Board at that time. Importantly, this decision is not attributed to any disagreements with the company regarding its operations, policies, or practices, which suggests a smooth transition and continued stable governance. As a consequence of Mr. Schwieters' retirement, the size of the Danaher Board will be reduced from thirteen to twelve members following his departure. This structural adjustment is a notable point for investors to consider regarding board composition and governance. The filing also includes the standard interactive data file exhibit.
View all 8-K filings →